Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
Overall survival of 3664 patients with multiple myeloma, according to... | Download Scientific Diagram
Frontiers | Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Blog Archives - Multiple Myeloma - Survival Rate Statistics by Hospital
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - Clinical Lymphoma, Myeloma and Leukemia
Disparities in Care and Outcomes
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes - Landgren - 2017 - Journal of Internal Medicine - Wiley Online Library
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal
Mayo Clinic Rochester Publishes Updated Multiple Myeloma Survival Rates! - Multiple Myeloma - Survival Rate Statistics by Hospital
Figure 1 from Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. | Semantic Scholar
Age-dependent overall survival of 2,907 newly diagnosed Danish patients... | Download Scientific Diagram
Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients | PLOS ONE
Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry | Haematologica
Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma - ScienceDirect
Trends in overall survival and costs of multiple myeloma, 2000–2014 | Leukemia
Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
![The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2f9746ff-a56a-4d1f-9fa7-5e6b9f11a6ee/gr1_lrg.jpg "The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The")
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Myeloma survival statistics | Cancer Research UK
Impact of Novel Therapies on Multiple Myeloma Survival– Current and Future Outcomes - Clinical Lymphoma, Myeloma and Leukemia
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience | Cancer Communications | Full Text
Improved long-term survival in multiple myeloma up to the age of 80 years | Leukemia
